The detection, treatment, and biology of epithelial ovarian cancer

Journal of Ovarian Research

Volumn 3, Issue 1, 2010, Pages

  Gubbels, Jennifer Aa ^a   Claussen, Nick ^b   Kapur, Arvinder K ^b   Connor, Joseph P ^b   Patankar, Manish S ^b  

^a AUGUSTANA COLLEGE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABAGOVOMAB; ACA 125; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CISPLATIN; CRS 207; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GONADOTROPIN; HUMAN EPIDIDYMIS PROTEIN 4; IDIOTYPIC ANTIBODY; MESOTHELIN; MONOMETHYLAURISTATIN E; MONOMETHYLAURISTATIN F; MORAB 009; ORAL CONTRACEPTIVE AGENT; OREGOVOMAB; PLATINUM DERIVATIVE; PROTEIN; PROTEIN P53; SS1P; TAXANE DERIVATIVE; TPD52 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; APOPTOSIS; BASEMENT MEMBRANE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CELL TRANSFORMATION; CLEAR CELL CARCINOMA; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DNA FRAGMENTATION; ENDOMETRIOID CARCINOMA; EPITHELIUM; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GERM CELL TUMOR; HUMAN; HYSTERECTOMY; INNATE IMMUNITY; LYMPHADENOPATHY; LYMPHOCYTE PROLIFERATION; MESOTHELIOMA; METASTASIS; MUCINOUS CARCINOMA; MUELLERIAN DUCT; OVARIECTOMY; OVARY CANCER; OVARY SURFACE EPITHELIUM; OVULATION; PANCREAS CANCER; PARANEOPLASTIC SYNDROME; PERITONEAL BIOPSY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; STROMA; T LYMPHOCYTE; THEORY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

EID: 77953372621     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-3-8     Document Type: Review

References (130)

1. Cancer statistics, 2008. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun, CA Cancer J Clin 2008 58 71 96 10.3322/CA.2007.0010 18287387 (Pubitemid 351521864)
2. Prognostic factors in ovarian cancer. ML Friedlander, Semin Oncol 1998 25 305 314 9633842
3. Epidemiology of ovarian cancer. J Permuth-Wey T Sellers, Methods Mol Biol 2009 472 413 43719107446
4. The temporal stability of the Symptom Index among women at high-risk for ovarian cancer. KA Lowe MR Andersen N Urban P Paley CW Dresher BA Goff, Gynecol Oncol 2009 114 225 230 10.1016/j.ygyno.2009.03.015 19427026
5. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. MR Andersen BA Goff KA Lowe N Scholler L Bergan CW Dresher P Paley N Urban, Cancer 2008 113 484 489 10.1002/cncr.23577 18615684
6. Development of an ovarian cancer symptom index: possibilities for earlier detection. BA Goff LS Mandel CW Drescher N Urban S Gough KM Schurman J Patras BS Mahony MR Andersen, Cancer 2007 109 221 227 10.1002/cncr.22371 17154394 (Pubitemid 46106236)
7. Ovarian cancer: epidemiology, biology, and prognostic factors. C Holschneider J Berek, Semin Surg Oncol 19 3 10 10.1002/1098-2388(200007/08)19: 1<3::AID-SSU2>3.0.CO;2-S 10883018
8. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. A Antoniou PD Pharoah S Narod HA Risch JE Eyfjord JL Hopper N Loman H Olsson O Johannsson A Borg B Pasini P Radice S Manoukian DM Eccles N Tang E Olah H Anton-Culver E Warner J Lubinski J Gronwald B Gorski H Tulinius S Thorlacius H Eerola H Nevanlinna K Syrjakoski OP Kallioniemi D Thompson C Evans J Peto et al. Am J Hum Genet 2003 72 1117 1130 10.1086/375033 12677558 (Pubitemid 36530000)
9. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. SC Rubin I Benjamin K Behbakht H Takahashi MA Morgan VA LiVolsi A Berchuck MG Muto JE Garber BL Weber HT Lynch J Boyd, N Engl J Med 1996 335 1413 1416 10.1056/NEJM199611073351901 8875917 (Pubitemid 26382501)
10. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. MC King JH Marks JB Mandell, Science 2003 302 643 646 10.1126/science.1088759 14576434 (Pubitemid 37310920)
11. Reciprocal interactions between human ovarian surface epithelial cells and adjacent extracellular matrix. PA Kruk VJ Uitto JD Firth S Dedhar N Auersperg, Exp Cell Res 1994 215 97 108 10.1006/excr.1994.1320 7525326 (Pubitemid 24339179)
12. Ovarian surface epithelium: biology, endocrinology, and pathology. N Auersperg AS Wong KC Choi SK Kang PC Leung, Endocr Rev 2001 22 255 288 10.1210/er.22.2.255 11294827 (Pubitemid 32458162)
13. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. DC Connolly R Bao AY Nikitin KC Stephens TW Poole X Hua SS Harris BC Vanderhyden TC Hamilton, Cancer Res 2003 63 1389 1397 12649204 (Pubitemid 36348722)
14. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. N Ahmed E Thompson M Quinn, J Cell Physiol 2007 213 581 588 10.1002/jcp.21240 17708542 (Pubitemid 350058249)
15. Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA. W Neunteufel G Breitenecker, Gynecol Oncol 1989 32 297 302 10.1016/0090-8258(89)90628-8 2646183 (Pubitemid 19074917)
16. Effects of epidermal growth factor/hydrocortisone on the growth and differentiation of human ovarian surface epithelium. C Salamanca S Maines-Bandiera P Leung Y Hu N Auersperg, J Soc Gynecol Investig 2004 11 241 251 10.1016/j.jsgi.2003.10.010 15120699 (Pubitemid 38561370)
17. Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. N Ahmed S Maines-Bandiera M Quinn W Unger S Dedhar N Auersperg, Am J Physiol Cell Physiol 2006 290 1532 1542 10.1152/ajpcell.00478.2005 16394028 (Pubitemid 43830793)
18. Pathology of ovarian cancer precursors. R Scully, J Cell Biochem Suppl 1995 23 208 218 10.1002/jcb.240590928 8747398 (Pubitemid 26032877)
19. Incessant ovulation - a factor in ovarian neoplasia? MF Fathalla, Lancet 1971 2 163 10.1016/S0140-6736(71)92335-X 4104488
20. Focus on epithelial ovarian cancer. RF Ozols MA Bookman DC Connolly MB Daly AK Godwin RJ Schilder X Xu TC Hamilton, Cancer Cell 2004 5 19 24 10.1016/S1535-6108(04)00002-9 14749123 (Pubitemid 38121593)
21. Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. JR Testa LA Getts H Salazar Z Liu LM Handel AK Godwin TC Hamilton, Cancer Res 1994 54 2778 2784 8168110 (Pubitemid 24173774)
22. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. AK Godwin JR Testa LM Handel Z Liu LA Vanderveer PA Tracey TC Hamilton, J Natl Cancer Inst 1992 84 592 601 10.1093/jnci/84.8.592 1556770
23. Development of a syngeneic mouse model for events related to ovarian cancer. KF Roby CC Taylor JP Sweetwood Y Cheng JL Pace O Tawfik DL Persons PG Smith PF Terranova, Carcinogenesis 2000 21 585 591 10.1093/carcin/21.4.585 10753190 (Pubitemid 30214011)
24. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. S Tworoger K Fairfield G Colditz B Rosner S Hankinson, Am J Epidemiol 2007 166 894 901 10.1093/aje/kwm157 17656616 (Pubitemid 47511685)
25. Determinants of ovarian cancer risk. I. Reproductive experiences and family history. DW Cramer GB Hutchison WR Welch RE Scully KJ Ryan, J Natl Cancer Inst 1983 71 711 716 6578366 (Pubitemid 14232384)
26. Factors affecting the association of oral contraceptives and ovarian cancer. DW Cramer GB Hutchison WR Welch RE Scully RC Knapp, N Engl J Med 1982 307 1047 1051 7121514 (Pubitemid 12027061)
27. Review: gonadotropins and development of ovarian cancer. I Konishi H Kuroda M Mandai, Oncology 1999 57 Suppl 2 45 48 10.1159/000055274 10545802 (Pubitemid 29494884)
28. Ovulation-induced DNA damage in ovarian surface epithelial cells of ewes: prospective regulatory mechanisms of repair/survival and apoptosis. W Murdoch R Townsend A McDonnel, Biol Reprod 2001 65 1417 1424 10.1095/biolreprod65.5.1417 11673258 (Pubitemid 33031499)
29. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? L Dubeau, Gynecol Oncol 1999 72 437 442 10.1006/gyno.1998.5275 10053122 (Pubitemid 29118208)
30. The cell of origin of ovarian epithelial tumours. L Dubeau, Lancet Oncol 2008 9 1191 1197 10.1016/S1470-2045(08)70308-5 19038766
31. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. MJ Callahan CP Crum F Medeiros DW Kindelberger JA Elvin JE Garber CM Feltmate RS Berkowitz MG Muto, J Clin Oncol 2007 25 3985 3990 10.1200/JCO.2007.12.2622 17761984 (Pubitemid 47477278)
32. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. A Finch M Beiner J Lubinski HT Lynch P Moller B Rosen J Murphy P Ghadirian E Friedman WD Foulkes C Kim-Sing T Wagner N Tung F Couch D Stoppa-Lyonnet P Ainsworth M Daly B Pasini R Gershoni-Baruch C Eng OI Olopade J McLennan B Karlan J Weitzel P Sun SA Narod, Jama 2006 296 185 192 10.1001/jama.296.2.185 16835424
33. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. CB Powell E Kenley LM Chen B Crawford J McLennan C Zaloudek M Komaromy M Beattie J Ziegler, J Clin Oncol 2005 23 127 132 10.1200/JCO.2005.04.109 15625367 (Pubitemid 41702631)
34. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. Y Lee A Miron R Drapkin MR Nucci F Medeiros A Saleemuddin J Garber C Birch H Mou RW Gordon DW Cramer FD McKeon CP Crum, J Pathol 2007 211 26 35 10.1002/path.2091 17117391 (Pubitemid 46092026)
35. Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations. A Saleemuddin A Folkins L Garrett J Garber M Muto C Crum S Tworoger, Gynecol Oncol 2008 111 226 232 10.1016/j.ygyno.2008. 07.018 18718648
36. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. AK Folkins EA Jarboe A Saleemuddin Y Lee MJ Callahan R Drapkin JE Garber MG Muto S Tworoger CP Crum, Gynecol Oncol 2008 109 168 173 10.1016/j.ygyno.2008.01.012 18342932
37. Extraovarian peritoneal serous papillary carcinoma. A clinicopathologic study of 31 cases. JC Dalrymple P Bannatyne P Russell HJ Solomon MH Tattersall K Atkinson J Carter P Duval P Elliott M Friedlander et al. Cancer 1989 64 110 115 10.1002/1097-0142(19890701)64:1<110::AID-CNCR2820640120>3.0.CO;2-5 2731107 (Pubitemid 19167146)
38. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. A Finch P Shaw B Rosen J Murphy SA Narod TJ Colgan, Gynecol Oncol 2006 100 58 64 10.1016/j.ygyno.2005.06.065 16137750 (Pubitemid 41815050)
39. Papillary serous carcinoma of the peritoneum. GL Fromm DM Gershenson EG Silva, Obstet Gynecol 1990 75 89 95 2296429
40. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. HM Davis VR Zurawski Jr RC Bast Jr TL Klug, Cancer Res 1986 46 6143 6148 2430690 (Pubitemid 17221746)
41. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. RC Bast Jr TL Klug E Schaetzl P Lavin JM Niloff TF Greber VR Zurawski Jr RC Knapp, Am J Obstet Gynecol 1984 149 553 559 6204531 (Pubitemid 14086185)
42. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. JM Niloff TL Klug E Schaetzl VR Zurawski Jr RC Knapp RC Bast Jr, Am J Obstet Gynecol 1984 148 1057 1058 6201072 (Pubitemid 14136410)
43. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. TL Klug RC Bast Jr JM Niloff RC Knapp VR Zurawski Jr, Cancer Res 1984 44 1048 1053 6198078
44. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. RC Bast Jr TL Klug E St John E Jenison JM Niloff H Lazarus RS Berkowitz T Leavitt CT Griffiths L Parker VR Zurawski Jr RC Knapp, N Engl J Med 1983 309 883 887 6310399
45. CA-125 in patients with endometriosis. RL Barbieri, Fertil Steril 1986 45 767 769 2423377
46. Elevated serum concentrations of CA-125 in patients with advanced endometriosis. RL Barbieri JM Niloff RC Bast Jr E Scaetzl RW Kistner RC Knapp, Fertil Steril 1986 45 630 634 3457709 (Pubitemid 16112281)
47. CA-125 in peritoneal fluid from patients with nonmalignant gynecologic disorders. MA Ismail J Rotmensch LJ Mercer BS Block GI Salti JA Holt, J Reprod Med 1994 39 510 512 7966039 (Pubitemid 24230834)
48. Use of CA125 fluctuation during the menstrual cycle as a tool in the clinical diagnosis of endometriosis; a preliminary report. H Kafali H Artuc N Demir, Eur J Obstet Gynecol Reprod Biol 2004 116 85 88 10.1016/j.ejogrb.2004.02. 039 15294374 (Pubitemid 39044500)
49. CA125 antigen levels in obstetric and gynecologic patients. JM Niloff RC Knapp E Schaetzl C Reynolds RC Bast Jr, Obstet Gynecol 1984 64 703 707 6208522 (Pubitemid 15205480)
50. Status of tumor markers in ovarian cancer screening. RJ Bast, J Clin Oncol 2003 21 200s 205s 10.1200/JCO.2003.01.068 12743135
51. The CA 125 gene: a newly discovered extension of the glycosylated N-terminal domain doubles the size of this extracellular superstructure. TJ O'Brien JB Beard LJ Underwood K Shigemasa, Tumour Biol 2002 23 154 169 10.1159/000064032 12218296 (Pubitemid 44858307)
52. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. TJ O'Brien JB Beard LJ Underwood RA Dennis AD Santin L York, Tumour Biol 2001 22 348 366 10.1159/000050638 11786729 (Pubitemid 34062947)
53. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. BW Yin A Dnistrian KO Lloyd, Int J Cancer 2002 98 737 740 10.1002/ijc.10250 11920644 (Pubitemid 34225625)
54. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. BW Yin KO Lloyd, J Biol Chem 2001 276 27371 27375 10.1074/jbc.M103554200 11369781 (Pubitemid 37410652)
55. Prevention and early detection of ovarian cancer: mission impossible? RJ Bast M Brewer C Zou M Hernandez M Daley R Ozols K Lu Z Lu D Badgwell G Mills S Skates Z Zhang D Chan A Lokshin Y Yu, Recent Results Cancer Res 2007 174 91 100 17302189
56. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. I Hellstrom KE Hellstrom, Adv Exp Med Biol 2008 622 15 21 18546615
57. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. I Hellstrom J Raycraft M Hayden-Ledbetter JA Ledbetter M Schummer M McIntosh C Drescher N Urban KE Hellstrom, Cancer Res 2003 63 3695 3700 12839961 (Pubitemid 36793054)
58. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. KH Lu AP Patterson L Wang RT Marquez EN Atkinson KA Baggerly LR Ramoth DG Rosen J Liu I Hellstrom D Smith L Hartmann D Fishman A Berchuck R Schmandt R Whitaker DM Gershenson GB Mills RC Bast Jr, Clin Cancer Res 2004 10 3291 3300 10.1158/1078-0432.CCR-03- 0409 15161682 (Pubitemid 38685433)
59. Potential markers that complement expression of CA125 in epithelial ovarian cancer. DG Rosen L Wang JN Atkinson Y Yu KH Lu EP Diamandis I Hellstrom SC Mok J Liu RC Bast Jr, Gynecol Oncol 2005 99 267 277 10.1016/j.ygyno.2005.06. 040 16061277 (Pubitemid 41502830)
60. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. I Simon Y Liu KL Krall N Urban RL Wolfert NW Kim MW McIntosh, Gynecol Oncol 2007 106 112 118 10.1016/j.ygyno.2007.03.007 17490732 (Pubitemid 46898578)
61. Serum and tissue measurements of CA72-4 in ovarian cancer patients. Y Negishi H Iwabuchi H Sakunaga M Sakamoto K Okabe H Sato G Asano, Gynecol Oncol 1993 48 148 154 10.1006/gyno.1993.1026 8381375 (Pubitemid 23075165)
62. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. A Berchuck GC Rodriguez A Kamel RK Dodge JT Soper DL Clarke-Pearson RC Bast Jr, Am J Obstet Gynecol 1991 164 669 674 1992720
63. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. A Berchuck A Kamel R Whitaker B Kerns G Olt R Kinney JT Soper R Dodge DL Clarke-Pearson P Marks et al. Cancer Res 1990 50 4087 4091 1972347 (Pubitemid 20225635)
64. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. AT Baron EM Cora JM Lafky CH Boardman MC Buenafe A Rademaker D Liu DA Fishman KC Podratz NJ Maihle, Cancer Epidemiol Biomarkers Prev 2003 12 103 113 12582019 (Pubitemid 36193999)
65. EGF/ErbB receptor family in ovarian cancer. NJ Maihle AT Baron BA Barrette CH Boardman TA Christensen EM Cora JM Faupel-Badger T Greenwood SC Juneja JM Lafky H Lee JL Reiter KC Podratz, Cancer Treat Res 2002 107 247 258 11775453
66. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. GB Mills A Eder X Fang Y Hasegawa M Mao Y Lu J Tanyi FH Tabassam J Wiener R Lapushin S Yu JA Parrott T Compton W Tribley D Fishman MS Stack D Gaudette R Jaffe T Furui J Aoki JR Erickson, Cancer Treat Res 2002 107 259 283 11775454
67. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. RG Moore AK Brown MC Miller S Skates WJ Allard T Verch M Steinhoff G Messerlian P DiSilvestro CO Granai RC Bast Jr, Gynecol Oncol 2008 108 402 408 10.1016/j.ygyno.2007.10.017 18061248 (Pubitemid 351174295)
68. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. GL Anderson M McIntosh L Wu M Barnett G Goodman JD Thorpe L Bergan MD Thornquist N Scholler N Kim K O'Briant C Drescher N Urban, J Natl Cancer Inst 102 26 38 20042715
69. Distribution pattern and risk factors of pelvic and para-aortic lymph node metastasis in epithelial ovarian carcinoma. N Tsumura N Sakuragi H Hareyama C Satoh M Oikawa H Yamada R Yamamoto K Okuyama T Fujino T Sagawa S Fujimoto, Int J Cancer 1998 79 526 530 10.1002/(SICI)1097-0215(19981023)79:5<526::AID- IJC14>3.0.CO;2-# 9761124 (Pubitemid 28445277)
70. WJ Hoskins CA Perez RC Young, Principles and Practice of Gynecologic Oncology Philadelphia: Limmincott-Raven Publishers 1997
71. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. DK Armstrong B Bundy L Wenzel HQ Huang R Baergen S Lele LJ Copeland JL Walker RA Burger, N Engl J Med 2006 354 34 43 10.1056/NEJMoa052985 16394300 (Pubitemid 43048949)
72. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. M Markman BN Bundy DS Alberts JM Fowler DL Clark-Pearson LF Carson S Wadler J Sickel, J Clin Oncol 2001 19 1001 1007 11181662 (Pubitemid 32176274)
73. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. DS Alberts PY Liu EV Hannigan R O'Toole SD Williams JA Young EW Franklin DL Clarke-Pearson VK Malviya B DuBeshter, N Engl J Med 1996 335 1950 1955 10.1056/NEJM199612263352603 8960474 (Pubitemid 26428219)
74. Factors affecting the completion of intraperitoneal chemotherapy in women with ovarian cancer. WR Robinson J Beyer, Int J Gynecol Cancer 20 70 74 20130505
75. Mechanisms of transcoelomic metastasis in ovarian cancer. DS Tan R Agarwal SB Kaye, Lancet Oncol 2006 7 925 934 10.1016/S1470-2045(06)70939-1 17081918 (Pubitemid 44615952)
76. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). JA Belisle JA Gubbels CA Raphael M Migneault C Rancourt JP Connor MS Patankar, Immunology 2007 122 3 418 29 10.1111/j.1365-2567.2007.02660.x 17617155 (Pubitemid 47556479)
77. Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC) development. C Chen C Zhang G Zhuang H Luo J Su P Yin J Wang, Cancer Invest 2008 26 965 974 10.1080/07357900801975256 19093253
78. Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells. JR Conejo-Garcia F Benencia MC Courreges PA Gimotty E Khang RJ Buckanovich KA Frauwirth L Zhang D Katsaros CB Thompson B Levine G Coukos, Cancer Res 2004 64 2175 2182 10.1158/0008-5472. CAN-03-2194 15026360 (Pubitemid 38339470)
79. Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. JR Conejo-Garcia F Benencia MC Courreges E Khang L Zhang A Mohamed-Hadley JM Vinocur RJ Buckanovich CB Thompson B Levine G Coukos, Cancer Biol Ther 2003 2 446 451 14508119
80. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. JP Connor M Felder, Gynecol Oncol 2008 111 330 335 10.1016/j.ygyno.2008.07.012 18723214
81. Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients. D Taylor D Bender C Gerçel-Taylor J Stanson T Whiteside, Br J Cancer 2001 84 1624 1629 10.1054/bjoc.2001.1847 11401315 (Pubitemid 32612493)
82. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. TS Migone J Zhang X Luo L Zhuang C Chen B Hu JS Hong JW Perry SF Chen JX Zhou YH Cho S Ullrich P Kanakaraj J Carrell E Boyd HS Olsen G Hu L Pukac D Liu J Ni S Kim R Gentz P Feng PA Moore SM Ruben P Wei, Immunity 2002 16 479 492 10.1016/S1074-7613(02)00283-2 11911831 (Pubitemid 34260924)
83. Correlation between expression of DcR3 on tumor cells and sensitivity to FasL. W Li C Zhang C Chen G Zhuang, Cell Mol Immunol 2007 4 455 460 18163957
84. Multicellular spheroids in ovarian cancer metastases: Biology and pathology. K Shield M Ackland N Ahmed G Rice, Gynecol Oncol 2009 113 1 143 8 10.1016/j.ygyno.2008.11.032 19135710
85. Ovarian cancer: strategies for overcoming resistance to chemotherapy. R Agarwal SB Kaye, Nat Rev Cancer 2003 3 502 516 10.1038/nrc1123 12835670 (Pubitemid 37328838)
86. Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. JR Chien G Aletti DA Bell GL Keeney V Shridhar LC Hartmann, J Cell Biochem 2007 102 1117 1129 10.1002/jcb.21552 17879946 (Pubitemid 350220033)
87. Tumor invasion and metastasis: an imbalance of positive and negative regulation. L Liotta W Stetler-Stevenson, Cancer Res 1991 51 5054s 5059s 1884381 (Pubitemid 121001258)
88. VTJ DeVita S Hellman SA Rosenberg, Cancer: Principles and Practice of Oncology lippincott Williams and Wilkins 7 2004
89. Tumor metastasis: mechanistic insights and clinical challenges. P Steeg, Nat Med 2006 12 895 904 10.1038/nm1469 16892035 (Pubitemid 44175140)
90. The clonal evolution of metastases from primary serous epithelial ovarian cancers. L Khalique A Ayhan J Whittaker N Singh I Jacobs S Gayther S Ramus, Int J Cancer 2009 124 7 1579 86 10.1002/ijc.24148 19123469
91. The distribution of secondary growths in cancer of the breast. 1889. S Paget, Cancer Metastasis Rev 1989 8 98 101 2673568
92. Mechanisms of metastasis. K Hunter N Crawford J Alsarraj, Breast Cancer Res 2008 10 Suppl 1 2 10.1186/bcr1988 19091006
93. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. A Rump Y Morikawa M Tanaka S Minami N Umesaki M Takeuchi A Miyajima, J Biol Chem 2004 279 9190 9198 10.1074/jbc.M312372200 14676194 (Pubitemid 38295982)
94. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. JA Gubbels J Belisle M Onda C Rancourt M Migneault M Ho TK Bera J Connor BK Sathyanarayana B Lee I Pastan MS Patankar, Mol Cancer 2006 5 50 10.1186/1476-4598-5-50 17067392 (Pubitemid 44742657)
95. A binding domain on mesothelin for CA125/MUC16. O Kaneko L Gong J Zhang J Hansen R Hassan B Lee M Ho, 2008 284 6 3739 49 19075018
96. The E-cadherin/catenin complex in invasion and metastasis. ME Bracke FM Van Roy MM Mareel, Curr Top Microbiol Immunol 1996 213 Pt 1 123 161 8814984
97. Establishment of an ovarian metastasis model and possible involvement of E-cadherin down-regulation in the metastasis. Y Kuwabara T Yamada K Yamazaki WL Du K Banno D Aoki M Sakamoto, Cancer Sci 2008 99 1933 1939 19016752
98. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. H Kajiyama K Shibata M Terauchi M Yamashita K Ino A Nawa F Kikkawa, Int J Oncol 2007 31 277 283 17611683
99. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. J Berek RJ Bast A Lichtenstein N Hacker C Spina L Lagasse R Knapp J Zighelboim, Obstet Gynecol 1984 64 708 714 6493663 (Pubitemid 15205481)
100. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. L Zhang JR Conejo-Garcia D Katsaros PA Gimotty M Massobrio G Regnani A Makrigiannakis H Gray K Schlienger MN Liebman SC Rubin G Coukos, N Engl J Med 2003 348 203 213 10.1056/NEJMoa020177 12529460 (Pubitemid 36077915)
101. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. JA Gubbels M Felder S Horibata JA Belisle A Kapur H Holden S Petrie M Migneault C Rancourt JP Connor MS Patankar, Mol Cancer 9 11 10.1186/1476-4598-9-11 20089172
102. Isolation and characterization of human natural killer cell subsets. M Cooper M Caligiuri, Curr Protoc Immunol 2004 Chapter 7 Unit 7.34 18432933
103. Ascites specific inhibition of CD1d-mediated activation of natural killer T cells. T Webb Rn Giuntoli O Rogers J Schneck M Oelke, Clin Cancer Res 2008 14 7652 7658 10.1158/1078-0432.CCR-08-1468 19047090
104. Ovarian carcinoma cells inhibit T cell proliferation: suppression of IL-2 receptor beta and gamma expression and their JAK-STAT signaling pathway. H Wang X Xie WG Lu DF Ye HZ Chen X Li Q Cheng, Life Sci 2004 74 1739 1749 10.1016/j.lfs.2003.07.051 14741732 (Pubitemid 38117101)
105. NKG2D ligands in tumor immunity. N Nausch A Cerwenka, Oncogene 2008 27 5944 5958 10.1038/onc.2008.272 18836475
106. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. V Groh J Wu C Yee T Spies, Nature 2002 419 734 738 10.1038/nature01112 12384702 (Pubitemid 35177960)
107. Tumor-derived soluble MICs impair CD3(+)CD56(+) NKT-like cell cytotoxicity in cancer patients. H Wang D Yang W Xu Y Wang Z Ruan T Zhao J Han Y Wu, Immunol Lett 2008 120 65 71 10.1016/j.imlet.2008.07.001 18672004
108. Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. K Li M Mandai J Hamanishi N Matsumura A Suzuki H Yagi K Yamaguchi T Baba S Fujii I Konishi, Cancer Immunol Immunother 2009 58 641 652 10.1007/s00262-008-0585-3 18791713
109. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13 - evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. AA Noujaim BC Schultes RP Baum R Madiyalakan, Cancer Biother Radiopharm 2001 16 187 203 10.1089/10849780152389384 11471484 (Pubitemid 32641217)
110. Immunotherapy of human ovarian carcinoma with OvaRex MAb-B43.13 in a human-PBL-SCID/BG mouse model. BC Schultes C Zhang LY Xue AA Noujaim R Madiyalakan, Hybridoma 1999 18 47 55 10.1089/hyb.1999.18.47 10211788 (Pubitemid 29140421)
111. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Berek P Taylor W McGuire L Smith B Schultes C Nicodemus, J Clin Oncol 2009 27 418 425 10.1200/JCO.2008.17.8400 19075271
112. Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13. RP Baum AA Noujaim A Nanci V Moebus A Hertel A Niesen B Donnerstag T Sykes G Boniface G Hor, Hybridoma 1993 12 583 589 10.1089/hyb.1993.12.583 8300134 (Pubitemid 24198149)
113. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Y Chen S Clark T Wong Y Chen Y Chen MS Dennis E Luis F Zhong S Bheddah H Koeppen A Gogineni S Ross P Polakis W Mallet, Cancer Res 2007 67 4924 4932 10.1158/0008-5472.CAN-06- 4512 17510422 (Pubitemid 46910200)
114. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. JR Junutula H Raab S Clark S Bhakta DD Leipold S Weir Y Chen M Simpson SP Tsai MS Dennis Y Lu YG Meng C Ng J Yang CC Lee E Duenas J Gorrell V Katta A Kim K McDorman K Flagella R Venook S Ross SD Spencer W Lee Wong HB Lowman R Vandlen MX Sliwkowski RH Scheller P Polakis et al. Nat Biotechnol 2008 26 925 932 10.1038/nbt.1480 18641636
115. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. J Pfisterer A du Bois J Sehouli S Loibl S Reinartz A Reuss U Canzler A Belau C Jackisch R Kimmig K Wollschlaeger V Heilmann F Hilpert, Ann Oncol 2006 17 1568 1577 10.1093/annonc/mdl357 17005631 (Pubitemid 44548850)
116. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. P Sabbatini J Dupont C Aghajanian F Derosa E Poynor S Anderson M Hensley P Livingston A Iasonos D Spriggs W McGuire S Reinartz S Schneider C Grande S Lele K Rodabaugh J Kepner S Ferrone K Odunsi, Clin Cancer Res 2006 12 5503 5510 10.1158/1078-0432.CCR-05-2670 17000686 (Pubitemid 44497267)
117. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer. S Reinartz A Hombach S Kohler H Schlebusch D Wallwiener H Abken U Wagner, Cancer Res 2003 63 3234 3240 12810653 (Pubitemid 36735877)
118. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. R Hassan AT Remaley ML Sampson J Zhang DD Cox J Pingpank R Alexander M Willingham I Pastan M Onda, Clin Cancer Res 2006 12 447 453 10.1158/1078-0432.CCR-05-1477 16428485 (Pubitemid 43166134)
119. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). P Argani C Iacobuzio-Donahue B Ryu C Rosty M Goggins RE Wilentz SR Murugesan SD Leach E Jaffee CJ Yeo JL Cameron SE Kern RH Hruban, Clin Cancer Res 2001 7 3862 3868 11751476 (Pubitemid 34044602)
120. Mesothelin is not required for normal mouse development or reproduction. TK Bera I Pastan, Mol Cell Biol 2000 20 2902 2906 10.1128/MCB.20.8.2902-2906. 2000 10733593 (Pubitemid 30183509)
121. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. M Ho R Hassan J Zhang QC Wang M Onda T Bera I Pastan, Clin Cancer Res 2005 11 3814 3820 10.1158/1078-0432.CCR-04-2304 15897581 (Pubitemid 40685601)
122. Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts. R Hassan V Broaddus S Wilson D Liewehr J Zhang, Clin Cancer Res 2007 13 7166 7171 10.1158/1078-0432.CCR-07-1592 18056197 (Pubitemid 350276903)
123. Mesothelin targeted cancer immunotherapy. R Hassan M Ho, Eur J Cancer 2008 44 46 53 10.1016/j.ejca.2007.08.028 17945478 (Pubitemid 350262830)
124. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. R Hassan W Ebel EL Routhier R Patel JB Kline J Zhang Q Chao S Jacob H Turchin L Gibbs MD Phillips S Mudali C Iacobuzio-Donahue EM Jaffee M Moreno I Pastan PM Sass NC Nicolaides L Grasso, Cancer Immun 2007 7 20 18088084
125. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. R Hassan C Schweizer KF Lu B Schuler AT Remaley SC Weil I Pastan, Lung Cancer 2009 19744744
126. Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines. G Sinnathamby P Lauer J Zerfass B Hanson A Karabudak J Krakover AA Secord TM Clay MA Morse TW Dubensky Jr DG Brockstedt R Philip M Giedlin, J Immunother 2009 32 856 869 10.1097/CJI.0b013e3181b0b125 19752748
127. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. PT Kaumaya KC Foy J Garrett SV Rawale D Vicari JM Thurmond T Lamb A Mani Y Kane CR Balint D Chalupa GA Otterson CL Shapiro JM Fowler MR Grever TS Bekaii-Saab WE Carson, J Clin Oncol 2009 27 5270 5277 10.1200/JCO.2009.22.3883 19752336
128. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF. JD Lewis LA Sullivan JA Byrne W de Riese RK Bright, Cancer Immunol Immunother 2009 58 1337 1349 10.1007/s00262-009-0659-x 19169682
129. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. V Goodell LG Salazar N Urban CW Drescher H Gray RE Swensen MW McIntosh ML Disis, J Clin Oncol 2006 24 762 768 10.1200/JCO.2005.03.2813 16391298 (Pubitemid 46622043)
130. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. N Leffers AJ Lambeck MJ Gooden BN Hoogeboom R Wolf IE Hamming BG Hepkema PH Willemse BH Molmans H Hollema JW Drijfhout WJ Sluiter AR Valentijn LM Fathers J Oostendorp AG van der Zee CJ Melief SH van der Burg T Daemen HW Nijman, Int J Cancer 2009 125 2104 2113 10.1002/ijc.24597 19621448